2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 404

Long-Term Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 780

Long-Term Prognosis and Factors Associated with Damage Accrual in Japanese Patients with Systemic Lupus Erythematosus
Abstract Number: 1633

Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months
Abstract Number: 2765

Long-Term Retention Rate of First Biologics in Patients of Age over 75 Years with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Abstract Number: 3111

Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α (GM–CSFR-α) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 1649

Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment
Abstract Number: 1795

Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-
Abstract Number: 2431

Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis
Abstract Number: 2759

Long-Term Survival of Biological Therapy in Rheumatoid Arthritis Elderly Patients in Clinical Practice
Abstract Number: 1977

Long-Term Survival of Methotrexate in Giant Cell Arteritis Patients in Clinical Practice
Abstract Number: 2854

Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study
Abstract Number: 1225

Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Abstract Number: 891

Long-Term Use of Rituximab for Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 2864

Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies
Abstract Number: 2942

Longitudinal Analyses of Progression of Brain Athrophy in Childhood-Onset Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].